Drugmakers plan to raise U.S. prices on at least 350 branded medications including vaccines against COVID, RSV and shingles and blockbuster cancer treatment Ibrance, even as the Trump administration pressures them for cuts, according to data provided exclusively by healthcare research firm 3 Axis Advisors, Reuters reports. The increases do not reflect any rebates to pharmacy benefit managers and other discounts. Pfizer (PFE), Sanofi (SNY), Boehringer Ingelheim, Novartis (NVS) and GSK (GSK) are among those companies and also plan to raise prices on some drugs on January 1, the publication adds.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Moderately bullish activity in Pfizer with shareslittle changed
- Pfizer Completes Early-Stage Acne Trial, Signaling Quiet Expansion in Dermatology
- Option traders moderately bearish in Pfizer with shares down 0.14%
- Mixed options sentiment in Pfizer with shares up 0.66%
- Pfizer’s Protonix Pediatric Study Completion: What Investors Should Watch Next